SG Americas Securities LLC Purchases 44,806 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA)

SG Americas Securities LLC lifted its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 62.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,771 shares of the biopharmaceutical company’s stock after purchasing an additional 44,806 shares during the period. SG Americas Securities LLC’s holdings in Akebia Therapeutics were worth $222,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of Akebia Therapeutics by 10.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 9,662 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Akebia Therapeutics by 25.7% in the third quarter. MetLife Investment Management LLC now owns 68,064 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 13,907 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Akebia Therapeutics by 205.8% in the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 31,137 shares during the last quarter. Empirical Asset Management LLC acquired a new stake in Akebia Therapeutics during the 3rd quarter valued at approximately $44,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in Akebia Therapeutics during the 2nd quarter worth approximately $44,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

Insider Buying and Selling

In related news, CAO Richard C. Malabre sold 30,202 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $63,424.20. Following the completion of the sale, the chief accounting officer now directly owns 280,248 shares of the company’s stock, valued at $588,520.80. The trade was a 9.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Steven Keith Burke sold 50,506 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $106,062.60. Following the completion of the transaction, the senior vice president now owns 816,234 shares in the company, valued at approximately $1,714,091.40. The trade was a 5.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 280,579 shares of company stock valued at $589,216 over the last ninety days. 4.10% of the stock is owned by corporate insiders.

Akebia Therapeutics Price Performance

NASDAQ AKBA opened at $2.14 on Friday. The stock has a market capitalization of $466.91 million, a P/E ratio of -9.30 and a beta of 0.74. The business has a 50 day simple moving average of $2.01 and a 200 day simple moving average of $1.68. Akebia Therapeutics, Inc. has a one year low of $0.80 and a one year high of $2.48.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The firm had revenue of $37.43 million for the quarter, compared to the consensus estimate of $45.66 million. During the same period last year, the business posted ($0.08) earnings per share. Equities analysts expect that Akebia Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

AKBA has been the topic of a number of analyst reports. StockNews.com lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of Akebia Therapeutics in a research report on Thursday, January 23rd.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.